Life Sciences

Caixa Capital Risc acquires a stake in AlgaEnergy, leader in innovation in the microalgae sector

• CriteriaCaixa’s venture capital management company and the CDTI fund Innvierte Economía Sostenible will have a minority stake in the company.
• AlgaEnergy develops and markets biological agricultural inputs that increase the productivity and quality of crops in a sustainable and profitable way, as well as cosmetic and nutrition products, always with a focus on sustainability and functionality for the user.
• This transaction consolidates the growth strategy of the industrial area of Caixa Capital Risc, which channels its new investments through Criteria Industrial Ventures.
• Caixa Capital Risc manages a volume of more than €230 million in over 120 innovative companies in Spain and Portugal.

| Read more |

Medlumics raises €14M in a Series E financing co-led by Asabys Partners, VI Partners and CDTI Innvierte, together with existing investors Andera Partners, Caixa Capital Risc and Innogest

• Medlumics develops a unique real-time, photonically guided radiofrequency (RF) irrigated ablation catheter to improve the treatment of Atrial Fibrillation
• The proceeds from the Series E financing will be used to complete the preclinical development and obtain first in human data
•Medlumics strong investor syndicate includes Asabys Partners, VI Partners, Andera Partners, Caixa Capital Risc, Innogest Capital and CDTI Innvierte

| Read more |

Minoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and Macau

• Sperogenix will receive exclusive rights to develop and commercialize leriglitazone for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-threatening neurological condition
• Minoryx will receive an upfront and milestone payments of up to $78 million, as well as double digit royalties on annual net sales

| Read more |

Caixa Capital Risc is leading the largest operation in the biotech sector in Spain, with a €55 million financing round in Sanifit

• The financing ends with a loan capitalisation of €17 million, which brings the total of the operation to 72.2 million.
• It will speed up research into SNF472, a drug designed to treat a rare disease known as calciphylaxis.
• Two new investors are joining the company: Columbus Venture Partners and Alta Life Sciences.

| Read more |

Minoryx Therapeutics announces first patient dosed in the FRAMES phase 2 trial in Friedreich’s Ataxia

June 4, 2019- Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces that the first patient has been dosed with its lead candidate, leriglitazone (MIN-102), in the phase 2 FRAMES clinical trial in Friedreich’s Ataxia.

| Read more |